Gallbladder cancer (GC) is a rare malignancy but represents almost half of all biliary tract cancer. The chronic inflammation of the bile duct tissue accumulates successive genomic mutations that lead to malignant transformation. The most common mutations described are oncogenes K-RAS and tumor suppressors beta-catenin (CTNNB1). The majority of histopathology changes in gallbladder cancer appear as adenocarcinomas (90%). Gallbladder cancer patients are frequently asymptomatic at presentation or